Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
A bad situation gets worse – again – and rivals seek to capitalise.
What goes down must come up.
Device deal making is back in a big way, despite the munificence of venture funds.
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.